Copyright
©The Author(s) 2019.
World J Diabetes. Aug 15, 2019; 10(8): 446-453
Published online Aug 15, 2019. doi: 10.4239/wjd.v10.i8.446
Published online Aug 15, 2019. doi: 10.4239/wjd.v10.i8.446
Anti-atherosclerotic effect | Decrease matrix metalloproteinase 2; decrease vascular smooth muscle cell proliferation |
Improves endothelial function | Increase nitric oxide-induced vasodilation; decrease oxidative stress |
Anti-inflammatory effect | Suppress human macrophagesby inhibition of protein kinase C |
Decrease infarct/injury size | Decrease glucose-induced apoptosis; decrease intracellular calcium overload |
Modifies risk factors | Improve glycemic control; decrease body weight; decrease blood pressure; decrease low-density lipoprotein |
- Citation: Dogruel H, Balci MK. Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role intreatment; from the past to future. World J Diabetes 2019; 10(8): 446-453
- URL: https://www.wjgnet.com/1948-9358/full/v10/i8/446.htm
- DOI: https://dx.doi.org/10.4239/wjd.v10.i8.446